Previous 10 | Next 10 |
The American Association of Liver Diseases Annual Meeting, better known as The Liver Meeting, will open in Boston on Nov. 8. Data will be presented on new therapies for diseases ranging from hepatitis to non-alcoholic steatohepatitis (NASH), which affect hundreds of thousands, if not millions, o...
Investment thesis: Biotechnology investors work on the assumption that news surrounding assets in clinical development impact company valuation significantly. Our analysis suggests that focusing on earlier events, such as Phase 2 and 3 data release, represents a stronger short-term, cataly...
Shares of Assembly Biosciences (NASDAQ: ASMB) , a clinical-stage biopharmaceutical company, jumped for the second day in a row. There was a lot to unpack in a pair of abstracts released on Wednesday that will accompany a late-breaking poster presentation at the American Association for t...
Thinly traded micro cap Assembly Biosciences ( ASMB +45.4% ) is up on a 13x surge in volume. Shares have almost doubled in two days in response to positive data on HBV candidates ABI-H0731 and ABI-H2158. The results will be presented at The Liver Meeting in Boston next month. More...
Gainers: Hepion Pharmaceuticals (NASDAQ: HEPA ) +64% . Assembly Biosciences (NASDAQ: ASMB ) +41% . Professional Diversity Network (NASDAQ: IPDN ) +31% . Synthesis Energy Systems (NASDAQ: SES ) +23% . Limelight Networks (NASDAQ: LLNW ) +21% . CARBO Ceramics (NYSE: CRR ) +21% . E...
Shares of Assembly Biosciences (NASDAQ: ASMB) gained over 41% today after the company announced an update on its hepatitis B virus (HBV) programs. The first update, from a phase 2a study evaluating the lead drug candidate ABI-H0731, suggests that the pipeline asset is effective in red...
Gainers: Viveve Medical (NASDAQ: VIVE ) +91% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +71% . Regional Health Properties (NYSEMKT: RHE ) +53% . Xenetic Biosciences (NASDAQ: XBIO ) +44% . Assembly Biosciences (NASDAQ: ASMB ) +30% . Ideal Power (NASDAQ: IPWR ) +29% . Aethlon Me...
Assembly Biosciences (NASDAQ: ASMB ) initiated with Buy rating and $20 (115% upside) price target at Mizuho Securities. More news on: Assembly Biosciences, Inc., Avid Bioservices, Inc., Axsome Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Phase 2a studies of ABI-H0731 + nucleos(t)ide analogs (Nrtl) in HBeAg+ patients show faster and deeper declines in HBV DNA and RNA with combination than Nrtl alone, as well as subsequent declines in the surrogate markers of cccDNA with long-term treatment Potent antiviral activity obse...
Cancer patients who receive an antibiotic within one month of receiving a checkpoint inhibitor achieve a median survival of just two months. Those who don't take an antibiotic and receive the same treatment achieve a median survival of 26 months, fully 1,200% longer. The significant gap is thoug...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...